Ilixadencel improves responses and survival in metastatic kidney cancer

Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of  newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February. Ilixadencel is an immune primer designed to increase the body’s […]

read more

Follow-up data from phase I/II clinical trial with INTUVAX in kidney cancer shows promise

Follow-up data from a phase I/II clinical trial with INTUVAX in eleven patients with metastatic kidney cancer have been announced by Immunicum, a Swedish biopharmaceutical company. The trial was started in February 2012, and 5 patients are still alive. The median overall survival for the entire patient group has more than doubled, and the median overall […]

read more
Showing all 2 results